N/A
Completed N=5
Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia
Source: ClinicalTrials.gov NCT01878604 ↗
Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Feb 2017
Primary outcomePrimary: Number of LDLR Gene Mutations — 7 gene mutations
Summary
Identify new or novel genes which may impact on cholesterol level, and establish the relationship between those gene mutations with atherosclerosis, as well as responses to lipid-lowering drugs.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of LDLR Gene Mutations |
7 | — |
| SECONDARY LDL-C Reduction Percentage |
48.16 | — |
Eligibility Criteria
Inclusion criteria
Patients of any age and sex who meet clinical or genetic criteria for hoFH as follows:
- Cutaneous xanthomata before the age of ten years
- LDLC > 13 mmol/L before treatment or > 7.76 mmol/L despite treatment
- Phenotypic features in keeping with HeFH in both parents
Exclusion criteria
Inability of patient, or, if less than 18, a parent, to sign informed consent.
Data sourced from ClinicalTrials.gov (NCT01878604). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.